Is HDL quality a good candidate for novel therapeutic target of cardiovascular disease?

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09130
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular medicine
• Research Institution: National Cardiovascular Center Research Institute
• Principal Investigator: Ogura Masatsune 国立研究開発法人国立循環器病研究センター, 研究所, 室長 (30532486)
• Co-Investigator(Renkei-kenkyūsha): HARADA-SHIBA Mariko 国立循環器病研究センター, 研究所, 部長 (70271575) ; MIYAMOTO Hiroshi 国立循環器病研究センター, 病院, 部長 (10312224) ; WATANABE Makoto 国立循環器病研究センター, 病院, 医長 (40343446) ; ASAUMI Yasuhide 国立循環器病研究センター, 病院, 医長 (20629315)
• Research Collaborator: MORIMOTO Megumu
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: HDL機能 / HDLコレステロール / 家族性高コレステロール血症 / 一般住民コホート / コレステロール引き抜き能 / 抗酸化能

Outline of Final Research Achievements

Drug interventions that increase high-density lipoprotein cholesterol (HDL-C), which was thought as “the good cholesterol”, have not reduced cardiovascular events in patients already prescribed statin. These evidences support the importance of HDL functionalities over the simple measurement of HDL-C levels. We demonstrated both cholesterol efflux capacity and anti-oxidant property were better surrogate markers for predicting atherosclerotic cardiovascular disease (ASCVD) than HDL-C levels in patients with familial hypercholesterolemia. Moreover, we investigated the association between cholesterol efflux capacity and incident ASCVD outcomes in a Japanese general population cohort (The Suita study). We found cholesterol efflux capacity was inversely associated with the incidence of all ASCVD events. Further studies are needed to identify the determinants of HDL functionalities. It will lead to develop novel biomarkers and drugs to reduce residual risks after LDL lowering therapy.

Free Research Field

脂質代謝学